title: Removal of non-transferrin-bound iron from blood with iron overload using a device with immobilized desferrioxamine.
abstract: An extracorporeal hollow-fiber device with immobilized desferrioxamine (DFO) was developed for the removal of nontransferrin-bound iron (NTBI) from blood, without the toxicity of parenteral chelation. When blood circulates through the fibers having pores with 30 kD cut-off, non-transferrin-bound-iron (NTBI) crosses the fiber pores and is chelated by the immobilized desferrioxamine. Removal of circulating iron stimulates iron release from larger proteins and tissue stores, establishing continuous iron flow to the immobilized chelator. During in vitro circulation through a device, iron removed from blood of hemodialysis or sickle cell patients was proportional to, but always in less than 50% of the initial iron level. We attribute the inability to remove more serum iron to irreversible iron binding by transferrin. To investigate where removable and fixed iron was bound, iron binding proteins were analyzed in sera from six patients with genetic anemias and iron overload. Sera separated by sieving chromatography contained 1-14% of the iron in the < 30 kD protein pool, 26-48% was in the combined non-transferrin pools. Sera from hemochromatosis patients without iron overload did not contain NTBI. Circulation of hemochromatosis blood through the device removed one third of the iron, this came from all molecular weight fractions. Iron removal by the device from the < 30 kD pool appears to establish a disequilibrium, that stimulates continuous iron release from ligands with low iron affinity, renewing the pool in the < 30 kD range, which includes potentially toxic NTBI. Therapy with the chelator device having immobilized desferrioxamine should be beneficial for treatment of patients with iron overload.
authors.affiliation: State University of New York at Buffalo, School of Medicine, Department of Gynecology/Obstetrics, Buffalo General Hospital, Buffalo, New York 14203, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Ambrus
authors.forename: I
authors.initials: I
authors.lastname: Stadler
authors.forename: C A
authors.initials: CA
authors.lastname: Toumbis
authors.forename: A
authors.initials: A
authors.lastname: Stadler
authors.forename: S
authors.initials: S
authors.lastname: Anthone
authors.forename: R
authors.initials: R
authors.lastname: Anthone
authors.forename: P
authors.initials: P
authors.lastname: DeAlarcon
authors.forename: G
authors.initials: G
authors.lastname: Deshpande
authors.forename: J
authors.initials: J
authors.lastname: Conway
authors.forename: A O
authors.initials: AO
authors.lastname: Vladutiu
authors.forename: J L
authors.initials: JL
authors.lastname: Ambrus
mesh_terms: D000740:Anemia / Q000097:blood; D001803:Blood Transfusion; D005591:Chemical Fractionation / Q000295:instrumentation* / Q000379:methods*; D002648:Child; D002850:Chromatography, Gel; D003676:Deferoxamine / Q000378:metabolism*; D006432:Hemochromatosis / Q000097:blood; D006801:Humans; D007501:Iron / Q000097:blood* / Q000302:isolation & purification* / Q000378:metabolism; D007502:Iron Chelating Agents / Q000378:metabolism; D019190:Iron Overload / Q000097:blood*; D014168:Transferrin / Q000378:metabolism
chemical_list: D007502:Iron Chelating Agents; D014168:Transferrin; D007501:Iron; D003676:Deferoxamine